These systems create temporary micro-pathways, allowing the peptide to reach deeper epidermal layers more efficiently
Its good to see studies like this - when you have clear numbers, its easier to talk with patients without relying on just trust us. The risks are always there, but what matters is understanding their scale, not imagining the worst
SN has received grants and/or speakers fees from Bayer, Boehringer Ingelheim, Novartis, Novo Nordisk, AMGEN, Menarini
Even better, patients do not have to do any healing protocols after treatment
Why Immunogenicity Matters for GLP-1 Peptide Drugs Peptide-based therapeutics inherently carry a higher immunogenic risk than small molecules due to their size, sequence complexity, and structural similarity to endogenous proteins
*Correspondence: Brianna Atto, [email protected] Disclaimer All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers
.png)
.png.jpg)
